Well I have a lot of shares now, the most out of any other stock and that's because of the science.
The financing situation sucks I'm not gonna sugarcoat it, but eventually something is going to give either an offer for a buyout or a licensing deal. Is it taking a lot longer than expected? Yes, but long-term I think leronlimab is a potential blockbuster drug.
I will give you an example. Look at HUMIRA it started off as a typical human monoclonal antibody for Rheumatoid arthritis(RA). RA is an immunological disorder. HUMIRA stands for HU - Human M- monoclonal Iga antibody Rheumatoid arthritis. The point being is that it started off as only treating one indication and now treats multiple indications. It has ended up being worth a $15 billion a year drug.
What's my prediction? Well, pro-140 is also a monoclonal antibody granted it targets CCR5 instead of HUMIRA which targets TNF - tumor necrosis factor instead. The point is that if pro-140 can be adapted to cancer, multiple scelorisis, GVHD, HIV, and other indications then it too can eventually become a billion dollar blockbuster like Humira. Leronlimab has shown strong efficacy in HIV monotherapy with a 92% response rate which is very strong for a single agent. Other HIV drugs have to use 2 to 3 agents combined. The point being is that for Pro-140 not only may it be able to treat all these diseases but it may be a monoclonal antibody that severely avoids the side effects associated with other monoclonal antibodies.
